Chair and Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-081 Lublin, Poland.
Department of Human Physiology, Medical University of Lublin, 20-080 Lublin, Poland.
Cells. 2022 Feb 21;11(4):752. doi: 10.3390/cells11040752.
MiRNA-8074 is a molecule with the potential to regulate the expression of key genes related to the pathogenesis of multiple myeloma (MM), i.e., , , , and . We analyzed the predictive and prognostic value of miRNA-8074 expression in MM patients. In total, 105 newly diagnosed MM patients treated with thalidomide (n = 27), bortezomib (n = 41) and bortezomib with thalidomide (n = 37) were studied. For miRNA analysis, the column method and the Real-Time PCR technique with specific TaqMan Fast Advanced Master Mix and TaqMan probes were used. Factors that were associated with a significant reduction in progression-free survival (PFS) included: ECOG > 1, ISS stage III, low hemoglobin, thrombocytopenia, hypoalbuminemia, abnormal renal function, elevated creatinine, GFR < 60 mL/min/1.73 m, elevated LDH, del(17p), t(11;14), the use of a single drug regimen (thalidomide or bortezomib) and high miRNA-8074 expression (HR = 2.01, 95% CI: 1.16-3.49; = 0.0233). In addition to the known prognostic factors, such as ECOG > 1, Durie-Salmon stage III, diagnosis of light chain disease or non-secreting MM, renal failure, hypoalbuminemia, hypercalcemia, high β2-microglobulin, elevated LDH, and t(14;16), a high expression of miRNA-8074 was significantly associated with a higher risk of death (HR = 4.12, 95% CI: 2.20-7.70; = 0.0009). In summary, miRNA-8074 may be a useful diagnostic tool to assess the prognosis in MM patients.
miRNA-8074 是一种分子，具有调节多发性骨髓瘤（MM）发病机制相关关键基因表达的潜力，即 、 、 、和 。我们分析了 miRNA-8074 表达在 MM 患者中的预测和预后价值。共研究了 105 例新诊断的接受沙利度胺（n=27）、硼替佐米（n=41）和硼替佐米联合沙利度胺（n=37）治疗的 MM 患者。用于 miRNA 分析的方法是柱法和实时 PCR 技术，使用特定的 TaqMan Fast Advanced Master Mix 和 TaqMan 探针。与无进展生存期（PFS）显著缩短相关的因素包括：ECOG>1、ISS 期 III、低血红蛋白、血小板减少、低白蛋白血症、肾功能异常、肌酐升高、GFR<60 mL/min/1.73 m、升高的 LDH、del(17p)、t(11;14)、单一药物方案（沙利度胺或硼替佐米）的使用和高 miRNA-8074 表达（HR=2.01，95%CI：1.16-3.49；=0.0233）。除了已知的预后因素，如 ECOG>1、Durie-Salmon 期 III、轻链疾病或非分泌性 MM、肾衰竭、低白蛋白血症、高钙血症、高β2-微球蛋白、升高的 LDH 和 t(14;16)，miRNA-8074 的高表达与更高的死亡风险显著相关（HR=4.12，95%CI：2.20-7.70；=0.0009）。总之，miRNA-8074 可能是评估 MM 患者预后的有用诊断工具。
